Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Public Criticism Puts Pressure On Chinese Government To Reduce Drug Prices

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Chinese media recently reported that some drugs in hospitals are sold at 13 times their ex-factory prices, which led the National Development and Reform Commission to release new measures on drug pricing, UBS said June 23

You may also be interested in...



China's New Drug Price Policies Will Favor Big Distributors, Restrict Smaller Ones

SHANGHAI - China is releasing a series of new policies to fight bribery in the pharmaceutical industry and reduce drug prices, which will benefit large distributors such as SinoPharm, Shanghai Pharmaceutical Group and Jointown, said an expert in a Citi research conference call July 19

China's New Drug Price Policies Will Favor Big Distributors, Restrict Smaller Ones

SHANGHAI - China is releasing a series of new policies to fight bribery in the pharmaceutical industry and reduce drug prices, which will benefit large distributors such as SinoPharm, Shanghai Pharmaceutical Group and Jointown, said an expert in a Citi research conference call July 19

China's New Drug Price Policies Will Favor Big Distributors, Restrict Smaller Ones

New guidelines that tighten rules on profit-margin ceilings and lock in distributor mark-ups will have no negative impact on large distributors while forcing small companies to change their business model, industry organization exec says.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC075219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel